Skip Navigation


JAC Advance Access originally published online on May 9, 2005
Journal of Antimicrobial Chemotherapy 2005 55(6):853-859; doi:10.1093/jac/dki139
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/6/853    most recent
dki139v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Han, X. Y.
Right arrow Articles by Andrade, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Han, X. Y.
Right arrow Articles by Andrade, R. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions{at}oupjournals.org

Brevundimonas diminuta infections and its resistance to fluoroquinolones

Xiang Y. Han1,* and Roberto A. Andrade2

1 Section of Clinical Microbiology, The University of Texas M.D. Anderson Cancer Center, Unit 84, 1515 Holcombe Boulevard, Houston, TX 77030, USA; 2 Division of Infectious Diseases, Baylor College of Medicine, Houston, TX 77030, USA

* Corresponding author. Tel:+1-713-792-3515; Fax:+1-713-792-0936; Email: xhan{at}mdanderson.org

Objectives: To report infections caused by Brevundimonas diminuta and antibiotic studies of this Gram-negative bacterium.

Patients and methods: Seven patients with infection and eight bacterial strains were studied. Tests included antibiotic susceptibility and analysis of the DNA gyrase and topoisomerase genes and the effect of efflux pump inhibitor Phe-Arg-ß-naphthylamide (PANA).

Results: The patients all had underlying disease of cancer. The infections involved bloodstream (one case), intravascular catheter (four cases), urinary tract (one case) and pleural space (one case of empyema). Fever up to 39.2°C characterized these infections, which resolved upon treatment by combination antibiotics. Microbiologically, all organisms were resistant to multiple fluoroquinolones and cefepime, but were susceptible to amikacin, imipenem and ticarcillin/clavulanate. These quinolone-resistant B. diminuta strains were probably selected out by the prophylactic use of a quinolone in six of these patients. Additionally, the B. diminuta type strain ATCC 11568T that was isolated before the quinolone era from water was also resistant to ciprofloxacin and intermediate to levofloxacin, suggesting intrinsic quinolone resistance. The DNA gyrase and topoisomerase of six analysed strains all contained GyrA Ala-83 and Met-87, GyrB Leu-466 or Thr-466, and ParC Gln-57, Val-66 and Ala-80 that were probably the cause of fluoroquinolone resistance. PANA had nearly negligible effect.

Conclusions: B. diminuta is intrinsically resistant to fluoroquinolones and can be selected out to cause infections.

Keywords: B. diminuta , fluoroquinolone resistance , quinolones


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Int. J. Syst. Evol. Microbiol.Home page
X. Y. Han, F. S. Han, and J. Segal
Chromobacterium haemolyticum sp. nov., a strongly haemolytic species
Int J Syst Evol Microbiol, June 1, 2008; 58(6): 1398 - 1403.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.